AstraZeneca’s AZN second-quarter 2025 core earnings of $1.09 per American depositary share (ADS) came in line with the Zacks Consensus Estimate. Core earnings of $2.17 per share rose 10% year over ...

Bayer's rivalry with Boehringer Ingelheim in the development of medicines for HER2-mutated non-small cell lung cancer (NSCLC) ...

Antibody-drug conjugates are a growing class of biopharmaceuticals that combine the precision of monoclonal antibodies with ...

Lilly’s appeal of an earlier, negative recommendation from a key EMA committee has worked out in its favor, and puts the drug ...

Be hugged by an artificial 'muscle' in Japanese 'well-down' popup which involves relaxing into your natural self ...

Researchers who conducted a real-world analysis of trastuzumab deruxtecan found the drug to be effective in treating metastatic breast cancer, though survival outcomes did not reach clinical trial ...

Q2 2025 has demonstrated the pharmaceutical industry’s continued momentum in developing transformative therapies across ...

The Proteus Syndrome market is entering a pivotal decade, driven by increasing disease recognition, improving diagnostic techniques, development of genetic testing techniques and other innovative ...

DelveInsight’s Advanced Ovarian Cancer pipeline report depicts a robust space with 50+ active players working to develop 50+ ...

IHH Healthcare Berhad strengthens India presence through collaboration between Fortis Healthcare and Gleneagles Healthcare India for growth.

TOKYO -- Japanese pharmaceutical companies including Daiichi Sankyo and Fujifilm Holdings are increasing efforts to develop biopharmaceutical talent, aiming for 50% to 100% growth in such experts as ...

The Association of the British Pharmaceutical Industry (ABPI) has appointed Laura McMullin as vice president of the trade ...